2 recruiting, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Osteosarcoma in Adolescents and Young Adults: new trials by email Literature Review of Osteosarcoma in Adolescents and Young Adults trials Research Report on Osteosarcoma in Adolescents and Young Adults
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles - Osteosarcoma, Pediatric Osteosarcoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 530 | 2026-10-01 | 2026-10-13 |
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma High-dose Methotrexate - Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | Phase 2 | Recruiting | Wake Forest University Health Sciences | 46 | 2026-09-01 | 2026-10-13 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma Cabozantinib, Best Supportive Care (BSC) - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Terminated | Ipsen | 10 | 2024-11-22 | 2026-03-31 |
Osteosarcoma (3)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Bone Tissue (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Connective and Soft Tissue (3) · Sarcoma (3)
MAX protein, human (1) · Methotrexate (1) · cabozantinib (1)
Gustave Roussy, Cancer Campus, Grand Paris (1) · Ipsen (1) · Wake Forest University Health Sciences (1)
France (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · United States (2) · Belgium (1) · Canada (1) · Denmark (1) · Finland (1) · Germany (1) · Sweden (1) · United Kingdom (1)
2023 (2)